Company intelligence / Profile preview

Anosys, Inc.

Menlo Park, California, United Statesanosysitsolutions.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Early Phase I trials showed promising safety data in advanced NSCLC and melanoma patients who failed current therapies. A Phase II study was designed to demonstrate initial efficacy but was suspended[1][5].

Therapeutic areas: Oncology
Modalities: Exosome-based immunotherapies (acellular vesicle therapies)Cancer vaccines using dexosomes/exosomes
Industry: Biotech

Drug pipeline

2 assets

mage3 peptide-pulsed dendritic cell-derived exosomes

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

Licensing from Institut National de la Santé et de la Recherche Médicale (INSERM), Gustave-Roussy Institute, Curie Institute in France for patent rights on exosome technology[5].Aventis SA (France)Kirin Brewery Co. Ltd. (Japan)BankInvest Biomedical Venture (Denmark)

Beyond the preview

Go deeper on Anosys, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anosys, Inc..

Explore the full profile